Due to the rising rates of antimicrobial resistance, antibiotics with activity against drug-resistant gram-negative pathogens are essential. Antibiotics such as carbapenems, which have historically been reserved for later lines of therapy, are being used earlier in treatment, placing additional pressure on the already-limited gram-negative infection (GNI) armamentarium. Despite the approval of novel antibiotics such as Shionogi\u2019s Fetroja \/ Fetcroja, Innoviva\u2019s Xacduro, and AbbVie \/ Pfizer\u2019s Emblaveo, additional treatments with novel mechanisms of action that are effective in patients with drug-resistant infections are needed. Although the market is heavily genericized and cost-containment measures limit the commercial success of new therapies, innovative push-and-pull market approaches such as value-based pricing and de-linked drug reimbursement models continue to encourage and support antibiotics development.<\/p>\n
QUESTIONS ANSWERED<\/strong><\/p>\n Geographies<\/strong>: United States, France, Germany, Italy, Spain, United Kingdom, Japan<\/p>\n Primary research: <\/strong>Country-specific interviews with thought-leading infectious disease specialists. Survey data collected for this and other Clarivate research.<\/p>\n Epidemiology: <\/strong>Diagnosed events of GNIs by country, segmented by key infections; pathogens (E. coli, Pseudomonas, Acinetobacter, Klebsiella<\/em>); and resistance types.<\/p>\n Forecast: <\/strong>10-year, annualized, drug-level sales and patient share of key antibiotics through 2034, segmented by brands \/ generics and epidemiological subpopulations<\/p>\n Drug treatments: <\/strong>Coverage of key current and late-phase emerging therapies.<\/p>\n PRODUCT DESCRIPTION <\/strong><\/p>\n Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:<\/p>\n\n
\n